LLY’s Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
Eli Lilly LLY announced positive top-line data from two late-stage studies evaluating orforglipron, its once-daily oral GLP-1 pill, in patients with type II diabetes (T2D). The ACHIEVE-2 study compared three doses of orforglipron (3 mg, 12 mg and 36 mg) against AstraZeneca’s AZN blockbuster SGLT-2 inhibitor Farxiga (dapagliflozin) in adults with T2D inadequately controlled with metformin. […]
Weight loss drugs may curb alcohol use
A new study found that after a cocktail, study participants taking medications for diabetes and weight loss saw delayed effects from alcohol. There’s mounting evidence that popular drugs prescribed for diabetes management and weight loss—better known by trade names like Ozempic and Wegovy—could be effective in reducing alcohol use. The pilot study in Scientific Reports found […]
Researchers seek to explain why GLP-1 drugs reduce alcohol cravings
Glucagon-like peptide-1 drugs appear to slow the speed at which alcohol enters the bloodstream, which diminishes its effects on a person’s brain, a study says.
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Novo Nordisk NVO and Omeros Corporation OMER have announced the signing of a definitive asset purchase and license agreement for zaltenibart (formerly OMS906), a clinical-stage candidate targeting rare blood and kidney disorders. Under the agreement, Novo Nordisk will receive exclusive worldwide rights to develop and commercialize zaltenibart across all indications. Omeros will receive approximately $340 million […]
The rise of homemade GLP-1s #Shorts
Americans are cooking up their own Ozempic—here’s why that’s alarming. Read more: https://tinyurl.com/4jswaz53 #GLP1 #Weightloss #Podcast Sign up for our newsletter for the day’s top stories, from sports to movies to politics to world events: https://profile.usatoday.com/newsletters/daily-briefing/
Weight loss with GLP-1 analogs in diabetes benefits stroke recovery
Drugs targeting the glucagon-like peptide 1 receptor (GLP-1R) offer several positive effects for individuals with type 2 diabetes, including the lowering of blood glucose and the reduction of body weight and of cardiovascular risk. In a study in mice, researchers at KI SÖS and Södersjukhuset have shown that the specific weight-loss properties of these treatments […]
STAT+: After hiring of a former top FDA official, Eli Lilly’s chief scientific officer isn’t fazed by revolving doors
As far as Eli Lilly’s Dan Skovronsky is concerned, the revolving door can spin in a good direction. The drugmaker last week hired Peter Marks, a former top U.S. Food and Drug Administration official, and the move quickly sparked a fresh round of concern about conflicts of interest between the agency and industry, as well […]
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
This retrospective cohort study examines whether taking glucagon-like peptide-1 receptor agonists is associated with increased risk of different cancers among patients with obesity.
STAT+: Novo strikes $2.1 billion deal with Omeros for rare disease drug
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today we catch up on some fascinating discussions from the STAT Summit, including talk of scaling therapies like the gene-editing treatment given to Baby KJ. Also, an oncologist talks about the importance of […]
Veteran biotech executive Clive Meanwell on drug pricing and the obesity market
On this week’s episode of “The Readout LOUD”: an interview with veteran biotech executive and company founder Clive Meanwell. Pfizer recently acquired one of Meanwell’s companies, the obesity drug developer Metsera, for just under $5 billion. Your favorite podcast co-hosts have been extra busy this week moderating panel discussions at the STAT Summit in Boston, […]